Boston Scientific (NYSE:BSX – Get Free Report) issued its earnings results on Wednesday. The medical equipment provider reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.01, FiscalAI reports. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.06 billion. During the same period in the prior year, the business posted $0.75 EPS. The business’s revenue was up 1.4% on a year-over-year basis.
Here are the key takeaways from Boston Scientific’s conference call:
- Q3 missed expectations: Organic revenue grew 1.5%, below the 3%–5% outlook, while adjusted EPS fell 3% to $0.73. The cybersecurity incident reduced revenue growth by roughly 300 basis points and EPS by approximately $0.07.
- Boston Scientific expects continued near-term pressure, guiding to a 1%–3% organic revenue decline and adjusted EPS of $0.77–$0.79 in Q4. Management said 2027 revenue and EPS growth will be challenging as EP and WATCHMAN face market-share and competitive pressures, while China pricing headwinds intensify.
- WATCHMAN sales declined 6% and EP sales declined 5% in Q3, with further EP share erosion expected until new products launch. The company also cited weaker urology performance, China-related pricing pressure, supply constraints, and delays affecting parts of its product pipeline.
- Management expects a return to stronger performance in 2028, supported by launches including FARAWAVE Ultra, 2D ICE, CRM’s Denali platform, new IVL and imaging technologies, and a potential Penumbra contribution. The company identified approximately $25 billion of new market opportunities by 2030.
- A company-wide restructuring program is expected to generate more than $500 million in savings over three years, with over half anticipated by the end of 2027. Boston Scientific said the program should improve operating leverage while preserving investment in key growth platforms.
Boston Scientific Trading Down 7.9%
Shares of BSX stock traded down $3.55 during trading on Wednesday, hitting $41.51. The company had a trading volume of 22,892,086 shares, compared to its average volume of 18,425,303. Boston Scientific has a one year low of $39.57 and a one year high of $105.65. The stock’s 50-day moving average price is $45.29 and its 200 day moving average price is $57.71.
Insider Activity
In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.
Trending Headlines about Boston Scientific
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Boston Scientific reported third-quarter revenue of $5.138 billion, up 1.5% year over year and ahead of analysts’ expectations of approximately $5.06 billion. Adjusted EPS of $0.73 also narrowly exceeded the $0.72 consensus estimate. Boston Scientific announces results for third quarter 2026
- Positive Sentiment: The company highlighted operational progress, including enrollment in the Elite AF clinical trial and FDA 510(k) clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Cardiovascular sales rose 1.9% on a reported basis, while Latin American sales increased 16%. Boston Scientific Reports third-quarter sales
- Neutral Sentiment: Management’s results extended Boston Scientific’s streak of quarterly earnings beats, but the underlying growth rate remains modest. Revenue increased from $5.065 billion a year earlier, while regional performance was uneven, including a 0.6% decline in Asia-Pacific sales. Boston Scientific Q3 adjusted earnings
- Negative Sentiment: Boston Scientific again lowered its fiscal 2026 outlook, now targeting approximately 4.25% reported net-sales growth. Management expects fourth-quarter reported and organic sales to decline 1% to 3%, signaling a difficult finish to the year. Boston Scientific cuts view after cyberattack
- Negative Sentiment: The cybersecurity incident has disrupted business operations and weighed on the company’s forecast. Investors appear to be treating the reduced guidance as more important than the quarterly beat, raising concerns about near-term execution and the duration of the incident’s financial impact. Boston Scientific cybersecurity attack weighs on guidance
- Negative Sentiment: Profitability also weakened year over year: GAAP EPS fell to $0.40 from $0.51, while adjusted EPS declined from $0.75 to $0.73. The combination of lower earnings, cybersecurity-related uncertainty and another outlook reduction explains the negative investor reaction. Boston Scientific Q3 2026 earnings
Wall Street Analyst Weigh In
BSX has been the subject of a number of analyst reports. Raymond James Financial restated an “outperform” rating and set a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Oppenheimer decreased their price objective on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a research report on Monday, September 21st. JPMorgan Chase & Co. cut their price target on Boston Scientific from $80.00 to $56.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Mizuho set a $55.00 price target on Boston Scientific in a research note on Tuesday, October 13th. Finally, The Goldman Sachs Group dropped their price objective on Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.93.
Read Our Latest Analysis on BSX
About Boston Scientific
Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.
Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.
Featured Articles
- Five stocks we like better than Boston Scientific
- Sherwin-Williams Remains Evergreen in a Frozen Housing Market
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
